Intas Launches First Biosimilar Lucentis, In India

India’s Intas is working on a well-thought out strategy for its newly launched Razumab, the first biosimilar version of Lucentis anywhere in the world. The plan is to ride lower costs to beat the innovator’s drug and also penetrate a market that is widely dependent on the off-label use of Avastin to treat wet age-related macular degeneration.